Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Research Article

ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2

Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, Nicholas P Andrews, Clifford G Tepper, June X Zou, Robert D Cardiff, Alexander D Borowsky and Hong-Wu Chen
Ekaterina V Kalashnikova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexey S Revenko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abigael T Gemo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas P Andrews
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clifford G Tepper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
June X Zou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert D Cardiff
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander D Borowsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong-Wu Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-10-1199
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chromatin coregulators are important players in tumorigenesis and cancer progression. ANCCA is an AAA+ ATPase-containing nuclear coactivator for the estrogen and androgen receptors that is crucial for assembly of chromatin modifying complexes and proliferation of hormone-responsive cancer cells. In this study, we show that ANCCA is overexpressed in >70% of breast tumors and that its high level correlates well with tumor histologic grades (P < 0.0001), highlighting ANCCA as a prognostic factor for poor overall survival and disease recurrence. Strikingly, high level ANCCA correlated with triple-negative tumors that represent highly aggressive disease. Analysis of ANCCA transcript levels in multiple expression profiles of breast cancer identified ANCCA as a common signature gene, indicating that elevated transcripts also strongly correlate with tumor metastasis and poor survival. Biological and mechanistic investigations revealed that ANCCA is crucial for proliferation and survival of triple negative/basal-like breast cancer cells and that it controls expression of B-Myb, histone methyltransferase EZH2 and an Rb-E2F core program for proliferation, along with a subset of key mitotic kinesins and cell survival genes (IRS2, VEGF and Akt1). In particular, ANCCA overexpression correlated strongly with EZH2 in tumors. Our results suggest that ANCCA may integrate multiple oncogenic programs in breast cancer, serving in particular as a prognostic marker and therapeutic target for triple-negative cancers.

  • Received April 6, 2010.
  • Revision received July 29, 2010.
  • Accepted August 24, 2010.
  • Copyright © 2010, American Association for Cancer Research.
Next
Back to top

Published OnlineFirst September 23, 2010
doi: 10.1158/0008-5472.CAN-10-1199

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2
Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, Nicholas P Andrews, Clifford G Tepper, June X Zou, Robert D Cardiff, Alexander D Borowsky and Hong-Wu Chen
Cancer Res September 23 2010 DOI: 10.1158/0008-5472.CAN-10-1199

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2
Ekaterina V Kalashnikova, Alexey S Revenko, Abigael T Gemo, Nicholas P Andrews, Clifford G Tepper, June X Zou, Robert D Cardiff, Alexander D Borowsky and Hong-Wu Chen
Cancer Res September 23 2010 DOI: 10.1158/0008-5472.CAN-10-1199
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement